Major Shareholder Exicure HiTron Sells $3.3M in EXICURE Stock, Reducing Stake to 40.7%
XCUR sits 86% above its 52-week low of $3.101.
Summary
Exicure HiTron Inc., a significant shareholder, sold 741,272 shares of EXICURE, INC. common stock for $3.3 million, reducing its beneficial ownership to 40.7%.
Key Events · Ownership and Investor Activity · XCUR
-
Major Shareholder Reduces Stake
Exicure HiTron Inc. sold 741,272 shares of EXICURE, INC. common stock on January 7, 2026.
-
Significant Transaction Value
The shares were sold at a price of $4.50 per share, totaling $3,335,724 in proceeds.
-
Post-Sale Ownership
Following the transaction, Exicure HiTron Inc. beneficially owns 2,592,061 shares, representing approximately 40.7% of the outstanding common stock.
-
Stated Purpose
The shares were transferred for liquidity purposes.
Analysis · XCUR · Life Sciences
This Schedule 13D/A reports a substantial sale of shares by Exicure HiTron Inc., a major institutional investor in EXICURE, INC. The sale of over $3.3 million worth of stock, representing a significant portion of the company's market capitalization and over 20% of Exicure HiTron's previous holdings, is a material reduction in their stake. While cited for "liquidity purposes," such a large disposition by a key shareholder can be interpreted negatively by the market, potentially signaling a shift in their investment thesis or a need for capital elsewhere. Investors should monitor future filings for further changes in ownership by this entity.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 34.9% of the 1159 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XCUR was trading at $5.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.5M. The 52-week trading range was $3.10 to $15.91. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.